All In Biotech

Drug Trial Radar · NCT01081678

Study To Assess FRacTure Healing With SclerosTin Antibody - Hip

A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Determine the Efficacy, Safety, and Tolerability of AMG 785 in Adults With a Fresh Unilateral Hip Fracture, Status Post Surgical Fixation

Last checked: Nov 20, 2026Latest source record: Sep 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 332 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

332

Actual

Start

Jun 20, 2010

Primary completion

Jun 30, 2012

Study completion May 10, 2013

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Mar 5, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 55 years, up to 95 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an international, multi-center study to determine the efficacy, safety, and tolerability of romosozumab (AMG 785) in adults with a fresh unilateral hip fracture, status post surgical fixation.

Conditions

  • Fracture Healing

Interventions

  • PlaceboDrug

    Administered by subcutaneous (under the skin) injection

  • RomosozumabDrug

    Administered by subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Timed-Up-and-Go (TUG) Over Week 6 Through Week 20Time frame: Weeks 6, 12, 16, and 20

Locations

99 sites in 24 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Pomona, California

  • Research Site

    Aurora, Colorado

  • Research Site

    Denver, Colorado

  • Research Site

    Indianapolis, Indiana

  • Research Site

    Woodbury, Minnesota

  • Research Site

    St Louis, Missouri

  • Research Site

    Brooklyn, New York

  • Research Site

    Rochester, New York

  • Research Site

    Altoona, Pennsylvania

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    State College, Pennsylvania

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    Liverpool, New South Wales, Australia

  • Research Site

    Footscray, Victoria, Australia

  • Research Site

    Bruges, Belgium

  • Research Site

    Genk, Belgium

  • Research Site

    Leuven, Belgium

  • Research Site

    Liège, Belgium

  • Research Site

    Liège, Belgium

  • Research Site

    Blagoevgrad, Bulgaria

  • Research Site

    Pleven, Bulgaria

  • Research Site

    Plovdiv, Bulgaria

  • Research Site

    Red Deer, Alberta, Canada

  • Research Site

    Cambridge, Ontario, Canada

  • Research Site

    Guelph, Ontario, Canada

  • Research Site

    Ottawa, Ontario, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Waterloo, Ontario, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Québec, Quebec, Canada

  • Research Site

    Québec, Quebec, Canada

  • Research Site

    Ã…rhus C, Denmark

  • Research Site

    Hvidovre, Denmark

  • Research Site

    København NV, Denmark

  • Research Site

    Viborg, Denmark

  • Research Site

    Tallinn, Estonia

  • Research Site

    Tartu, Estonia

  • Research Site

    Kuopio, Finland

Showing 40 of 99 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.